USAISR completes clinical study of OxyBand wound dressing

13 August 2012 (Last Updated August 13th, 2012 18:30)

The United States Army Institute of Surgical Research (USAISR) has completed a clinical trial of OxyBand Technologies' OxyBand wound dressing, designed to deliver therapeutic pure oxygen to damaged tissue.

The United States Army Institute of Surgical Research (USAISR) has completed a clinical trial of OxyBand Technologies' OxyBand wound dressing, designed to deliver therapeutic pure oxygen to damaged tissue.

By using a directional permeable gas-emitting reservoir, pure oxygen is packaged into a discrete wound dressing to heal wounds faster with less pain and inflammation.

The USAISR clinical trial assessed the efficacy of OxyBand wound dressing compared to a standard dressing.

Oxyband Technologies founder and CEO Dr Amie Franklin said the new findings showed OxyBand healed wounds significantly faster, with less pain and inflammation and without infection, when compared to placebo and standard-care dressings.

"Oxyband is grateful to the US Army Institute for Surgical Research and the burn center for conducting the clinical trial to compare OxyBand wound dressing to standard care," Franklin said.

"We are honored to have partnered with the US Army USAISR, a centre of excellence for battlefield health, trauma and burn research and care."

USAISR said it will present the OxyBand wound dressing results at the Military Health System Research Symposium (MHSRS), held on 13 -16 August 2012 at the Harbor Beach Marriott Hotel in Fort Lauderdale, Florida, US.

OxyBand wound dressings will be available through McKesson-Medical Surgical, a medical distributor of vital medicines, medical supplies and information technologies, according to the company.